新云社 update: Pfizer on November 18 signed an exclusive licensing agreement with Starna Therapeutics for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. Pfizer gains exclusive development, manufacturing and commercialization rights outside Greater China. The deal includes milestone payments of up to $2.3 billion.
Pfizer Licenses Three in vivo CAR-T Programs from Starna Therapeutics in Deal Worth Up to $2.3B
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
31m ago
Bitcoin Drops 8% as Crypto Liquidations Hit $2.38 Billion
38m ago
Bitcoin Falls Below $56K to $55,555, Down 53.8% From Record High
47m ago
Ether Falls to Near $1,550, Down About 35% in Four Weeks
1h ago
Argentina approves LNG project under large-investment incentive scheme
1h ago
JackYi: Market Drop Tied to Global Financial Risk, Not Crypto Data
1h ago
NDRC Holds Video Meeting on Government Investment Fund Disbursement and Project Reserves




